Living Cell Technologies Limited – OTC:LVCLY

Living Cell Technologies Limited stock price today

$0.048
+0.01
+56.86%
Financial Health
0
1
2
3
4
5
6
7
8
9

Living Cell Technologies Limited stock price monthly change

-38.00%
month

Living Cell Technologies Limited stock price quarterly change

-10.92%
quarter

Living Cell Technologies Limited stock price yearly change

-35.42%
year

Living Cell Technologies Limited key metrics

Market Cap
9.73M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
N/A
Revenue
N/A
EBITDA
-3.01M
Income
-3.12M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Living Cell Technologies Limited stock price history

Living Cell Technologies Limited stock forecast

Living Cell Technologies Limited financial statements

Living Cell Technologies Limited (OTC:LVCLY): Profit margin
Sep 2021 0 -367.00K
Dec 2021 0 -734.00K
Jun 2022 3.40K -1.22M -35926.49%
Jun 2023 42.01K -801.13K -1906.75%
Living Cell Technologies Limited (OTC:LVCLY): Debt to assets
Dec 2021 4455821 377.73K 8.48%
Sep 2022 3115902 382.76K 12.28%
Dec 2022 3115902 382.76K 12.28%
Jun 2023 4211959 449.85K 10.68%
Living Cell Technologies Limited (OTC:LVCLY): Cash Flow
Jun 2021 -835.88K 105.85K -18.31K
Dec 2021 -597.55K 43.30K 3.39M
Jun 2022 -1.44M -3.80K 1.29M
Jun 2023 -833.79K -4.11M 1.85M

Living Cell Technologies Limited alternative data

Living Cell Technologies Limited (OTC:LVCLY): Employee count
Apr 2024 48
May 2024 48
Jun 2024 48
Jul 2024 48

Living Cell Technologies Limited other data

  • What's the price of Living Cell Technologies Limited stock today?

    One share of Living Cell Technologies Limited stock can currently be purchased for approximately $0.05.

  • When is Living Cell Technologies Limited's next earnings date?

    Unfortunately, Living Cell Technologies Limited's (LVCLY) next earnings date is currently unknown.

  • Does Living Cell Technologies Limited pay dividends?

    No, Living Cell Technologies Limited does not pay dividends.

  • How much money does Living Cell Technologies Limited make?

    Living Cell Technologies Limited has a market capitalization of 9.73M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1133.95% to 42.02K US dollars.

  • What is Living Cell Technologies Limited's stock symbol?

    Living Cell Technologies Limited is traded on the OTC under the ticker symbol "LVCLY".

  • What is Living Cell Technologies Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Living Cell Technologies Limited?

    Shares of Living Cell Technologies Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Living Cell Technologies Limited went public?

    Living Cell Technologies Limited is publicly traded company for more then 18 years since IPO on 17 Jul 2007.

  • What is Living Cell Technologies Limited's official website?

    The official website for Living Cell Technologies Limited is lctglobal.com.

  • Where are Living Cell Technologies Limited's headquarters?

    Living Cell Technologies Limited is headquartered at 330 Collins Street, Melbourne, VIC.

  • How can i contact Living Cell Technologies Limited?

    Living Cell Technologies Limited's mailing address is 330 Collins Street, Melbourne, VIC and company can be reached via phone at +61 3 8689 9997.

Living Cell Technologies Limited company profile:

Living Cell Technologies Limited

lctglobal.com
Exchange:

OTC

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.

330 Collins Street
Melbourne, VIC 2000

:
ISIN: US53838R1077
: